Efficacy of Extracorporeal Shock Wave Therapy on Spasticity
Launched by KAYSERI CITY HOSPITAL · Jan 17, 2024
Trial Information
Current as of June 12, 2025
Completed
Keywords
ClinConnect Summary
Group 1 (n:20): BoNT-A was injected into the affected gastrocnemius muscle under ultrasonography guidance at doses recommended by standard guidelines and appropriate for the patient (50 IU to the medial head, 25 IU to the lateral head). In addition, conventional physical therapy exercises (stretching exercises, range of motion (ROM) exercises, neurophysiologic exercises, and gait exercises) were applied to the patients five days a week for four weeks.
Group 2 (n:20): In addition to the treatments (BoNT-A injection and exercise) in Group 1, one week after the injection, a total of 4 session...
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Being diagnosed with stroke according to the definition of the World Health Organization in 1989
- • Having a stroke confirmed by computed tomography (CT) and magnetic resonance imaging (MRI)
- • Being aged over 18 years
- • Having a MAS score of 1 and above for gastrocnemius, the plantar flexor muscle of the ankle
- • Having a stable general condition after a stroke
- • Giving consent to participate in the study.
- Exclusion criteria:
- • Having a fixed contracture in the ankle
- • Having no spasticity in the soleus, the plantar flexor muscle of the ankle
- • Previous antispastic surgery performed on the area
- • Change in antispastic drug use in the last six months, if any
- • Injection of BoNT-A, alcohol, phenol, or any other substance into the area in the last six months
- • Active infection or cancer at the application site
- • Having a cardiac pacemaker
- • Having bleeding diathesis
- • Having vascular complaints such as deep vein thrombosis, venous stasis, phlebitis, arterial disease
- • Being pregnant
- • Having neuromuscular junction disease or motor neuron disease
- • Having a known allergy to BoNT-A
- • 12. Active use of aminoglycosides or other antibiotic groups.
About Kayseri City Hospital
Kayseri City Hospital is a leading healthcare institution dedicated to advancing medical research and improving patient care through innovative clinical trials. As a prominent sponsor of clinical studies, the hospital combines state-of-the-art facilities with a multidisciplinary team of experienced healthcare professionals. Committed to enhancing therapeutic options and contributing to the scientific community, Kayseri City Hospital focuses on rigorous research protocols and ethical standards to ensure the safety and efficacy of new treatments. Through collaboration with academic institutions and industry partners, the hospital plays a vital role in translating research findings into practical applications that benefit patients and the broader healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kayseri, Kocasinan, Turkey
Patients applied
Trial Officials
HAVVA TALAY ÇALIŞ
Principal Investigator
KAYSERİ CITY HOSPITAL
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported